ArticlePloS one2013
Comparative analysis of ESBL-positive Escherichia coli isolates from animals and humans from the UK, The Netherlands and Germany.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.Lancet (London, England) · 2022Pooled it
- Comparative analysis of antimicrobial resistance in enterotoxigenic Escherichia coli isolates from two paediatric cohort studies in Lima, Peru.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2015Trial
- A One Health Comparative Study of MDRAntibiotics (Basel, Switzerland) · 2025Article
- Evidence of ESBL plasmid transfer and selective persistence of multiple host-associatedApplied and environmental microbiology · 2025Article
- Antimicrobial Resistance Patterns of ESBL-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Genomic insights into extended-spectrumJournal of medical microbiology · 2025Article
- Longitudinal study on the genetic diversity of extended-spectrum cephalosporin resistantFrontiers in microbiology · 2025Article
- Integration sites ofFrontiers in microbiology · 2025Article
- Antimicrobial resistance burden in India and Germany in 2022: A systematic analysis along with One Health perspective.Heliyon · 2024Article
- Antimicrobial Resistance in CommensalAntibiotics (Basel, Switzerland) · 2023Review
- Carriage of Extended Spectrum Beta Lactamase-ProducingAnimals : an open access journal from MDPI · 2023Article
- Article
- Dynamics of extended-spectrum cephalosporin resistance genes in Escherichia coli from Europe and North America.Nature communications · 2022Article
- Molecular identification ofJournal of advanced veterinary and animal research · 2022Article
- Multidrug-Resistant EnteropathogenicAntibiotics (Basel, Switzerland) · 2022Article
- Phenotyping and genotyping studies on extended-spectrum β-lactamase-producingVeterinary world · 2022Article
- Animal source food eating habits of outpatients with antimicrobial resistance in Bukavu, D.R. Congo.Antimicrobial resistance and infection control · 2021Article
- Antimicrobial Resistance ofAnimals : an open access journal from MDPI · 2021Article
- The Pheno- and Genotypic Characterization of PorcineMicroorganisms · 2021Article
- Antibiotic Resistance in Shiga ToxigenicAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
- Erratum issuedChattaway, Marie [added]
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The putative virulence and antimicrobial resistance gene contents of extended spectrum β-lactamase (ESBL)-positive E. coli (n=629) isolated between 2005 and 2009 from humans, animals and animal food products in Germany, The Netherlands and the UK were compared using a microarray approach to test the suitability of this approach with regard to determining their similarities. A selection of isolates (n=313) were also analysed by multilocus sequence typing (MLST). Isolates harbouring bla(CTX-M-group-1) dominated (66%, n=418) and originated from both animals and cases of human infections in all three countries; 23% (n=144) of all isolates contained both bla(CTX-M-group-1) and bla(OXA-1-like) genes, predominantly from humans (n=127) and UK cattle (n=15). The antimicrobial resistance and virulence gene profiles of this collection of isolates were highly diverse. A substantial number of human isolates (32%, n=87) did not share more than 40% similarity (based on the Jaccard coefficient) with animal isolates. A further 43% of human isolates from the three countries (n=117) were at least 40% similar to each other and to five isolates from UK cattle and one each from Dutch chicken meat and a German dog; the members of this group usually harboured genes such as mph(A), mrx, aac(6')-Ib, catB3, bla(OXA-1-like) and bla(CTX-M-group-1). forty-four per cent of the MLST-typed isolates in this group belonged to ST131 (n=18) and 22% to ST405 (n=9), all from humans. Among animal isolates subjected to MLST (n=258), only 1.2% (n=3) were more than 70% similar to human isolates in gene profiles and shared the same MLST clonal complex with the corresponding human isolates. The results suggest that minimising human-to-human transmission is essential to control the spread of ESBL-positive E. coli in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.